Compare RGP & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | CGEN |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.5M | 191.1M |
| IPO Year | 2000 | 2001 |
| Metric | RGP | CGEN |
|---|---|---|
| Price | $3.79 | $2.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $7.00 | $5.00 |
| AVG Volume (30 Days) | ★ 309.2K | 184.2K |
| Earning Date | 04-08-2026 | 05-18-2026 |
| Dividend Yield | ★ 6.85% | N/A |
| EPS Growth | ★ 79.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $452,006,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.06 | $1.38 |
| 52 Week High | $5.37 | $3.24 |
| Indicator | RGP | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 43.55 |
| Support Level | $3.47 | $2.34 |
| Resistance Level | $3.82 | $2.54 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 20.51 | 23.44 |
Resources Connection Inc is a professional services firm. Its segments include On-Demand Talent provides businesses with a go-to source for bringing in experts when its needed, serving the office of the CFO; Consulting drives transformation across people, processes and technology across domain areas including finance, technology and digital, risk and compliance and operational performance; Europe & Asia Pacific offers both on-demand and consulting services to clients throughout Europe and Asia Pacific; Outsourced Services; and Sitrick. It derives the majority of revenue from On-Demand Talent segment. Geographically, it operates in United States and internationally.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.